회사 개요
Kewaunee Scientific Corporation is engaged in the design, manufacture, and installation of specialized laboratory, healthcare, and technical furniture along with infrastructure products, serving diverse scientific and medical environments. The company operates within the Consumer Cyclical sector, specifically under the Furnishings, Fixtures & Appliances industry, which implies its performance is tied to economic cycles affecting capital expenditure in research and healthcare facilities. This enterprise maintains a market capitalization of $97.74M, generates annual revenue of $287.75M, and employs 1239 individuals across its operations. The combination of a sub-$100M market cap and nearly $300M in revenue indicates that the company functions as a small-cap entity with a revenue stream that is disproportionately large relative to its equity value, suggesting a high price-to-sales dynamic typical of niche industrial manufacturers. The scale of its workforce and revenue base reflects a stable operational footprint, yet the relatively small market valuation highlights a market perception that differs significantly from its top-line financial performance.
재무 건전성
The company reported revenue of $287.75M over the trailing twelve months, accompanied by net income of $11.08M and an EBITDA of $26.02M. The substantial gap between the $287.75M in revenue and the $11.08M in net income reveals a cost structure where operating expenses, including cost of goods sold, general and administrative costs, and interest expenses, consume approximately 96% of total sales before taxes and non-operating items. The free cash flow stands at $15.47M, which signifies that the company generates sufficient cash after capital expenditures to fund operations, pay down debt, or return capital, thereby providing a degree of financial flexibility despite its debt load. Profitability is characterized by a gross margin of 28.9%, an operating margin of 3.7%, and a profit margin of 3.9%, indicating that the company operates with thin margins where significant cost control is necessary to convert sales into earnings. On the balance sheet, cash holdings of $8.15M are significantly lower than total debt of $59.34M, resulting in a debt-to-equity ratio of 81.82%, which characterizes the company as a highly leveraged entity rather than one with a conservative capital structure. The current ratio of 2.12 suggests that the company holds more than double the amount of current assets relative to its current liabilities, indicating a comfortable buffer against short-term liquidity pressures. Return on Equity is reported at 17.4% while Return on Assets is 6.8%, revealing that management is effectively utilizing shareholder equity to generate returns, though the return on assets is moderated by the heavy debt load present on the balance sheet.
밸류에이션 평가
The trailing twelve-month P/E ratio is 9.17, while the forward P/E is projected at 15.79, implying that the market anticipates earnings growth sufficient to bridge the current low valuation to a higher multiple in the coming year. The price-to-book ratio stands at 1.38, which indicates that the market values the company at approximately 38% above its tangible book value, suggesting a modest premium for its intangible assets or growth prospects in the laboratory furniture niche. Alternative valuation metrics include a price-to-sales ratio of 0.34 and an EV/EBITDA of 5.79, which suggest that the stock is priced attractively relative to its sales and earnings before interest, taxes, depreciation, and amortization when compared to industry peers. The stock has traded between a 52-week high of $60.89 and a 52-week low of $30.33, and without the current price explicitly provided in the data, the valuation range defines the historical volatility envelope within which the stock trades. The beta of 0.67 indicates that the stock is less volatile than the broader market, moving with less intensity than the S&P 500, which offers a degree of downside protection during market corrections. These metrics collectively paint a picture of a low-priced, low-volatility stock that trades at a discount to its book value but commands a forward premium based on expected earnings recovery.
Growth & Income
Revenue growth year-over-year is recorded at 3.3%, whereas earnings growth year-over-year is -48.9%, demonstrating that earnings are shrinking significantly faster than revenue, which points to rising costs or declining margins rather than a top-line contraction. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all earnings are retained within the business to fund operations, debt service, or potential future investments rather than being distributed to shareholders. Consequently, the company reinvests its entire earnings stream back into the business model, relying on organic growth and capital efficiency to drive shareholder value instead of dividend income. This non-dividend profile combined with negative earnings growth suggests a capital-intensive reinvestment strategy where the market is waiting for margin expansion to drive future stock appreciation rather than relying on income generation.